These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

407 related items for PubMed ID: 8764380

  • 21. CYP2D6-debrisoquine hydroxylase gene polymorphism in multiple system atrophy.
    Planté-Bordeneuve V, Bandmann O, Wenning G, Quinn NP, Daniel SE, Harding AE.
    Mov Disord; 1995 May; 10(3):277-8. PubMed ID: 7651442
    [Abstract] [Full Text] [Related]

  • 22. Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients.
    LLerena A, de la Rubia A, Berecz R, Dorado P.
    Pharmacopsychiatry; 2004 Mar; 37(2):69-73. PubMed ID: 15048614
    [Abstract] [Full Text] [Related]

  • 23. CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans.
    Llerena A, Dorado P, Ramírez R, González I, Alvarez M, Peñas-Lledó EM, Pérez B, Calzadilla LR.
    Pharmacogenomics J; 2012 Apr; 12(2):176-83. PubMed ID: 21135868
    [Abstract] [Full Text] [Related]

  • 24. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.
    Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M.
    Mol Pharmacol; 1994 Sep; 46(3):452-9. PubMed ID: 7935325
    [Abstract] [Full Text] [Related]

  • 25. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population.
    Dahl ML, Johansson I, Palmertz MP, Ingelman-Sundberg M, Sjöqvist F.
    Clin Pharmacol Ther; 1992 Jan; 51(1):12-7. PubMed ID: 1346258
    [Abstract] [Full Text] [Related]

  • 26. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations.
    Wanwimolruk S, Bhawan S, Coville PF, Chalcroft SC.
    Eur J Clin Pharmacol; 1998 Jul; 54(5):431-5. PubMed ID: 9754989
    [Abstract] [Full Text] [Related]

  • 27. PCR-based CYP2D6 genotyping for Finnish lung cancer patients.
    Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Karjalainen A, Pelkonen O, Vainio H.
    Pharmacogenetics; 1993 Feb; 3(1):19-27. PubMed ID: 8097947
    [Abstract] [Full Text] [Related]

  • 28. Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes.
    Bertilsson L, Meese CO, Yue QY, Dahl ML, Ingelman-Sundberg M, Johansson I, Säwe J, Eichelbaum M.
    Pharmacogenetics; 1993 Apr; 3(2):94-100. PubMed ID: 8100167
    [Abstract] [Full Text] [Related]

  • 29. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?
    Løvlie R, Daly AK, Matre GE, Molven A, Steen VM.
    Pharmacogenetics; 2001 Feb; 11(1):45-55. PubMed ID: 11207030
    [Abstract] [Full Text] [Related]

  • 30. Identification of the primary gene defect at the cytochrome P450 CYP2D locus.
    Gough AC, Miles JS, Spurr NK, Moss JE, Gaedigk A, Eichelbaum M, Wolf CR.
    Nature; 1990 Oct 25; 347(6295):773-6. PubMed ID: 1978251
    [Abstract] [Full Text] [Related]

  • 31. Debrisoquine hydroxylation genotype in familial forms of idiopathic Parkinson's disease.
    Bordet R, Broly F, Destée A, Libersa C.
    Adv Neurol; 1996 Oct 25; 69():97-100. PubMed ID: 8615190
    [No Abstract] [Full Text] [Related]

  • 32. [Prevalence of ultraextensive drug metabolizers in Croatian population--long-PCR based detection of amplified CYP2D6 gene].
    Bozina N, Tramisak I, Granić P, Puljević D, Stavljenić-Rukavina A.
    Lijec Vjesn; 2002 Oct 25; 124(3-4):63-6. PubMed ID: 18958918
    [Abstract] [Full Text] [Related]

  • 33. Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6.
    Wang SL, Huang JD, Lai MD, Liu BH, Lai ML.
    Clin Pharmacol Ther; 1993 Apr 25; 53(4):410-8. PubMed ID: 8097442
    [Abstract] [Full Text] [Related]

  • 34. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity.
    Romkes-Sparks M, Mnuskin A, Chern HD, Persad R, Fleming C, Sibley GN, Smith P, Wilkinson GR, Branch RA.
    Carcinogenesis; 1994 Sep 25; 15(9):1955-61. PubMed ID: 7923590
    [Abstract] [Full Text] [Related]

  • 35. Molecular heterogeneity of the XbaI defined 44kb allele of the CYP2D locus within the Caucasian population.
    Mura C, Gerard N, Vincent-Viry M, Galteau MM, Jacqz-Aigrain E, Krishnamoorthy R.
    Br J Clin Pharmacol; 1993 Feb 25; 35(2):161-5. PubMed ID: 8095148
    [Abstract] [Full Text] [Related]

  • 36. An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis.
    Broly F, Marez D, Sabbagh N, Legrand M, Millecamps S, Lo Guidice JM, Boone P, Meyer UA.
    Pharmacogenetics; 1995 Dec 25; 5(6):373-84. PubMed ID: 8747409
    [Abstract] [Full Text] [Related]

  • 37. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use.
    Dorado P, Cáceres M, Pozo-Guisado E, Wong ML, Licinio J, Llerena A.
    Biotechniques; 2005 Oct 25; 39(10 Suppl):S571-4. PubMed ID: 18957039
    [Abstract] [Full Text] [Related]

  • 38. Metabolic activity of dextromethorphan O-demethylation in healthy Japanese volunteers carrying duplicated CYP2D6 genes: duplicated allele of CYP2D6*10 does not increase CYP2D6 metabolic activity.
    Ishiguro A, Kubota T, Ishikawa H, Iga T.
    Clin Chim Acta; 2004 Jun 25; 344(1-2):201-4. PubMed ID: 15149890
    [Abstract] [Full Text] [Related]

  • 39. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population.
    Aynacioglu AS, Sachse C, Bozkurt A, Kortunay S, Nacak M, Schröder T, Kayaalp SO, Roots I, Brockmöller J.
    Clin Pharmacol Ther; 1999 Aug 25; 66(2):185-92. PubMed ID: 10460072
    [Abstract] [Full Text] [Related]

  • 40. DNA haplotype dependency of debrisoquine 4-hydroxylase (CYP2D6) expression among extensive metabolisers.
    Mura C, Panserat S, Vincent-Viry M, Galteau MM, Jacqz-Aigrain E, Krishnamoorthy R.
    Hum Genet; 1993 Oct 25; 92(4):367-72. PubMed ID: 7901140
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.